Skip to content

Amniotic Fluid Analysis

Utility of Amniotic Fluid Analysis for Intrapartum Infection Prediction Model

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06131684
Enrollment
100
Registered
2023-11-14
Start date
2023-11-30
Completion date
2024-06-30
Last updated
2023-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetric Labor Complications

Brief summary

This is a prospective study that will aid in ensuring the feasibility of timely and correct aspiration of amniotic fluid by study research team that include the clinical team taking care of the patient during her labor, timely transport and interpretation of specimens. It will also assist in providing information for the computation of necessary statistical measures (e.g. sample size, power analysis, etc.) for the study cohorts that lack the needed data in the medical literature.

Detailed description

Can amniotic fluid be serially aspirated via an Intrauterine pressure catheter (IUPC) and successfully analyzed in labor? Do abnormal amniotic fluid results collected serially predict which laboring patients will develop an intrapartum infection? Can the results predict infection sooner than the current clinical diagnostic criteria as outlined by the 2015 NICHD guidelines? How do the sensitivity, specificity, positive and negative predictive values compare to the 2015 NICHD diagnostic criteria?

Interventions

DEVICEIntrauterine pressure catheter (IUPC) present

Amniotic fluid will be analyzed every 3 hours for the duration of labor for patients who require an IUPC through the standard of care.

DEVICEIntrauterine pressure catheter (IUPC) absent

Patients that do not require an IUPC through the standard of care will not have amniotic fluid analyzed.

Sponsors

Oregon Health and Science University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Singleton pregnancy * Gestational age ≥ 37 weeks * Age of participant ≥ 18 years old

Exclusion criteria

* Multiple gestation * Gestational age \< 37 weeks * Intrauterine fetal demise * Fetal anomalies * Pre-gestational Diabetics / Gestational Diabetics * Chronic immune suppression with steroids (defined as \> 1 month of consistent steroid use) * Oligohydramnios * Women with documented non-obstetric infections within 2 weeks of admission; including use of any antibiotics within 2 weeks of admission for non-documented/suspected infections * Repeat temperature not performed within 45 minutes of index fever (100.4 F) * Index fever (100.4 F) is \> 1 hour after delivery * Expectantly managed premature rupture of membranes

Design outcomes

Primary

MeasureTime frame
The number of patients who develop an intrapartum infectionFrom enrollment to delivery

Countries

United States

Contacts

Primary ContactWomen's Health Research Unit Department of Ob/Gyn
whru@ohsu.edu503-494-3666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026